Rubicon Research Limited (NSE:RUBICON)

India flag India · Delayed Price · Currency is INR
780.35
-7.30 (-0.93%)
At close: Feb 27, 2026
25.86%
Market Cap 128.56B
Revenue (ttm) 15.98B
Net Income (ttm) 2.06B
Shares Out 164.75M
EPS (ttm) 13.03
PE Ratio 59.87
Forward PE 42.35
Dividend n/a
Ex-Dividend Date n/a
Volume 75,701
Average Volume 257,138
Open 787.65
Previous Close 787.65
Day's Range 776.40 - 788.70
52-Week Range 570.75 - 822.00
Beta n/a
RSI 60.85
Earnings Date Feb 3, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, ... [Read more]

Industry Pharmaceutical Preparations
Founded 1999
Employees 903
Stock Exchange National Stock Exchange of India
Ticker Symbol RUBICON
Full Company Profile

Financial Performance

In fiscal year 2025, Rubicon Research's revenue was 12.84 billion, an increase of 50.40% compared to the previous year's 8.54 billion. Earnings were 1.34 billion, an increase of 47.63%.

Financial Statements

News

There is no news available yet.